Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
T-cell lymphoma peripheral | D016411 | — | — | — | 1 | — | — | 1 | 2 |
Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | 2 | — | — | — | 2 |
Carcinoma | D002277 | — | C80.0 | 1 | 2 | — | — | — | 2 |
Squamous cell carcinoma | D002294 | — | — | 1 | 2 | — | — | — | 2 |
Leukemia | D007938 | — | C95 | — | 1 | — | — | — | 1 |
Myeloid leukemia acute | D015470 | — | C92.0 | — | 1 | — | — | — | 1 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | — | 1 | — | — | — | 1 |
Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | — | 1 | — | — | — | 1 |
Myelodysplastic syndromes | D009190 | — | D46 | — | 1 | — | — | — | 1 |
Preleukemia | D011289 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
Non-small-cell lung carcinoma | D002289 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Tipifarnib |
INN | tipifarnib |
Description | Tipifarnib is a quinolone that is 1-methylquinolin-2-one which carries a 3-chlorophenyl and an amino(4-chlorophenyl)(1-methyl-imidazol-5-yl)methyl groups at the 4 and 6 positions, respectively (the R-isomer). It has a role as an antineoplastic agent, an EC 2.5.1.58 (protein farnesyltransferase) inhibitor and an apoptosis inducer. It is a quinolone, a member of monochlorobenzenes, a member of imidazoles and a primary amino compound. |
Classification | Small molecule |
Drug class | farnesyl transferase inhibitor |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cn1cncc1[C@@](N)(c1ccc(Cl)cc1)c1ccc2c(c1)c(-c1cccc(Cl)c1)cc(=O)n2C |
PDB | — |
CAS-ID | 192185-72-1 |
RxCUI | — |
ChEMBL ID | CHEMBL289228 |
ChEBI ID | — |
PubChem CID | 159324 |
DrugBank | DB04960 |
UNII ID | MAT637500A (ChemIDplus, GSRS) |